Aspire Biopharma Holdings, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation
Cayman Islands
Business Address
23150 FASHION DRIVE, SUITE 232, ESTERO, FL, 33928
Mailing Address
23150 FASHION DRIVE, SUITE 232, ESTERO, FL, 33928
Phone
561-704-8527
Fiscal Year End
1231
EIN
000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 30, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | February 24, 2026 | View on SEC |
| S-1 IPO registration statement | February 17, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 12, 2026 | View on SEC |
| 8-K Current report of material events | February 12, 2026 | View on SEC |
| 8-K Current report of material events | February 6, 2026 | View on SEC |
| 8-K Current report of material events | January 30, 2026 | View on SEC |
| 8-K Current report of material events | January 15, 2026 | View on SEC |
| 8-K Current report of material events | January 13, 2026 | View on SEC |
| 8-K Current report of material events | January 6, 2026 | View on SEC |
Annual Reports
10-K
March 30, 2026
- Secured $15 million in financing to fund operations through late 2026.
- Transitioning post-merger to streamline R&D and drug delivery systems.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.